Molecular attributes of dopamine receptors: New potential for antipsychotic drug development

Annals of Medicine

Volumn 28, Issue 3, 1996, Pages 211-219

  Hartman, Deborah S ^a   Civelli, Olivier ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Clozapine; D4; Neuroleptic; Schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; RECEPTOR SUBTYPE;

COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; DRUG DEVELOPMENT; EMOTION; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOLECULAR CLONING; MOTOR PERFORMANCE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA;

EID: 0029892902     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899609033122     Document Type: Review

References (77)

1. Andreasen NC. Schizophrenia: symptoms, signs, and diagnosis of schizophrenia. Lancet 1995; 346: 477-81.
2. Seeman P, Lee T, Chan-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-9.
3. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-3.
4. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179-86.
5. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979; 277: 93-6.
6. Bunzow JR, Van TH, Grandy DK, et al. Cloning and expression of a rat D2 dopamine receptor cDNA (see comments). Nature 1988; 336: 783-7.
7. Savarese TM, Fraser CM. In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors. Biochem J 1992; 283: 1-19.
8. Civelli O, Bunzow JR, Grandy DK. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 1993; 32: 281-307.
9. Fishburn CS, Belleli D, David C, Carmon S, Fuchs S. A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J Biol Chem 1993; 268: 5872-8.
10. Giros B, Martres MP, Pilon C, Sokoloff P, Schwartz JC. Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing. Biochem Biophys Res Commun 1991; 176: 1584-92.
11. Van Tol HHM, Wu CM, Guan H-C, et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149-52.
12. Lichter JB, Barr CL, Kennedy JL, Van Tol H, Kidd KK, Livak KJ. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993; 2: 767-73.
13. Livak KJ, Rogers J, Lichter JB. Variability of dopamine D4 receptor (DRD4) gene sequence within and among nonhuman primate species. Proc Natl Acad Sci USA 1995; 92: 427-31.
14. Nanko S, Hattori M, Ikeda K, Sasaki T, Kazamatsuri H, Kuwata S. Dopamine D4 receptor polymorphism and schizophrenia (letter; comment). Lancet 1993; 341: 689-90.
15. Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nat Genet 1996; 12: 81-4.
16. Ebstein RP, Novick O, Umansky R, et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet 1996; 12: 78-80.
17. Catalano M, Nobile M, Novelli E, Nothen MM, Smeraldi E. Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. Biol Psychiatry 1993; 34: 459-64.
18. Nothen MM, Cichon S, Hemmer S, et al. Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 1994; 3: 2207-12.
19. Murray AM, Hyde TM, Knable MB, et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995; 15: 2186-91.
20. Seeman P, Guan HC, Van Tol H. Dopamine D4 receptors elevated in schizophrenia (see comments). Nature 1993; 365: 441-5.
21. 4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 1995; 681: 109-16.
22. Schmauss C, Haroutunian V, Davis KL, Davidson M. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci USA 1993; 90: 8942-6.
23. Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146-51.
24. Matsumoto M, Hidaka K, Tada S, Tasaki Y, Yamaguchi T. Full-length cDNA cloning and distribution of human dopamine D4 receptor. Mol Brain Res 1995; 29: 157-62.
25. Meador-Woodruff JH, Grandy DK, Van Tol HHM, et al. Dopamine receptor gene expression in the human medial temporal lobe. Neuropschypharmacology 1994; 10: 239-48.
26. Cohen AI, Todd RD, Harmon S, O'Malley KL. Photoreceptors of mouse retinas possess D4 receptors coupled to adenylate cyclase. Proc Natl Acad Sci USA 1992; 89: 12093-7.
27. O'Malley KL, Harmon S, Tang L, Todd RD. The rat dopamine D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biologist 1992; 4: 137-46.
28. Bergson C, Mrzljak L, Lidow MS, Goldman-Rakic PS, Levenson R. Characterization of subtype-specific antibodies to the human D5 dopamine receptor: studies in primate brain and transfected mammalian cells. Proc Natl Acad Sci USA 1995; 92: 3468-72.
29. Jackson DM, Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry, and behavioral aspects. Pharmacol Ther 1994; 64: 291-369.
30. ix, proteins to inhibit adenylyl cyclase. J Biol Chem 1994; 269: 23120-7.
31. Guiramand J, Montmayeur J-P, Ceraline J, Bhatia M, Borrelli E. Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J Biol Chem 1995; 270: 7354-8.
32. Chio CL, Lajiness ME, Huff RM. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 1994; 45: 51-60.
33. Seabrook GR, Kemp JA, Freedman SB, Patel S, Sinclair HA, McAllister G. Functional expression of human D3 dopamine receptors in differentiated neuroblastoma x glioma NG108-15 cells. Br J Pharmacol 1994; 111: 391-3.
34. Pilon C, Lévesque D, Dimitriadou V, et al. Functional coupling of the human dopamine D3 receptor in a transfected NG108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol Mol Pharmacol 1994; 268: 129-39.
35. Tang L, Todd RD, Heller A, O'Malley KL. Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 1994; 268: 495-502.
36. McHale M, Coldwell MC, Herrity N, et al. Expression and functional characterisation of a synthetic version of the human D4 dopamine receptor in a stable human cell line. FEBS Lett 1994; 345: 147-50.
37. Chio CL, Drong RF, Riley DT, Gill GS, Slightom JL, Huff RM. D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J Biol Chem 1994; 269: 11813-9.
38. Mei YA, Griffon N, Buquet C, et al. Activation of dopamine D4 receptor inhibits an L-type calcium current in cerebellar granule cells. Neuroscience 1995; 68: 107-16.
39. Hillman DW, Lin D, Burnside B. Evidence for D4 receptor regulation of retinomotor movement in isolated teleost cone inner-outer segments. J Neurochem 1995; 64: 1326-35.
40. Zawilska JB, Nowak JZ. Dopamine receptor regulating serotonin N-acetyltransferase activity in chick retina represents a D4-like subtype: pharmacological characterization. Neurochem Int 1994; 24: 275-80.
41. Offermanns S, Simon MI. Galpha-15 and galpha-16 couple a wide variety of receptors to phospholipase C. J Biol Chem 1995; 270: 15175-80.
42. Frey U, Huang Y-Y, Kandel ER. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 1993; 260: 1661-4.
43. Surmeier DJ, Bargas J, Hemmlngs JHC, Nairn AC, Greengard P. Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron 1995; 14: 385-97.
44. Goldman-Rakic PS. Cellular basis of working memory. Neuron 1995; 14: 477.
45. Wenk GL, Pierce DJ, Struble RG, Price DL, Cork LC. Age-related changes in multiple neurotransmitter systems in the monkey brain. Neurobiol Aging 1989; 10: 11-9.
46. Goldman-Rakic PS, Brown RM. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 1981; 6; 177-87.
47. Arnsten AFT, Cai JX, Steere JC, Goldman-Rakic PS. Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J Neurosci 1995; 15: 3429-39.
48. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474-86.
49. Seeman P, Van Tol HHM. Dopamine D4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective. Eur J Pharm 1993; 233: 173-4.
50. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50: 322-8.
51. Cole JO, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1966; 10: 246-61.
52. Davis JM, Schaffer CB, Killian GA, et al. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980; 6: 70-87.
53. Cassens G, Inglis AK, Applebaum PS, Gutheil TG. Neuroleptics: effects of neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16: 477-99.
54. Ayd FR Jr. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054-60.
55. Coward DM. General pharmacology of clozapine. Br J Psychiatry 1992; 160 (Suppl 17): 5-11.
56. Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacology of schizophrenia. Acta Psychiatr Scand 1994; 90 (Suppl 384): 95-101.
57. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 1992; 160 (Suppl 17): 38-40.
58. Hartman DS, Monsma F, Civelli O. Interaction of antipsychotic drugs with dopamine receptor subtypes. In: Csernansky JG, ed. Handbook of Experimental Pharmacology. New York: Springer-Verlag, 1995: 43-75.
59. Asghari V, Schoots O, van Kats S, et al. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 1994; 46: 364-73.
60. Shaikh S, Collier DA, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993; 341: 116.
61. Flamez A, De Backer J-B, Wilczak N, Vauquelin G, De Keyser J. [3H]clozapine is not a suitable radioligand for the labelling of D4 dopamine receptors in postmortem human brain. Neurosci Lett 1994; 175: 17-20.
62. Glatt CE, Snowman AM, Sibley DR, Snyder SH. Clozapine: selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile. Mol Med 1995; 1: 398-406.
63. Beasley CM, Montgomery S, Tye NC. The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. Second International Conference on Schizophrenia, Vancouver, Canada, 1992.
64. Howard HR, Seeger TF. Novel antipsychotics. Ann Rep Medicinal Chem 1993; 28: 39-47.
65. Sayers AC, Burki HR, Ruch W, Asper H. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side effects. Psychopharmacology 1976; 51: 15-22.
66. Bartholini G. Interactions of striatal dopaminergic, cholinergic, and GABA-ergic neurons: relation to extrapyramidal function. Trends Pharmacol Sci 1980; 1: 138-40.
67. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995; 15 (Suppl 1): 24S-29S.
68. Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O. Seroquel (ICI; 204: 636), a putative 'atypical' antipsychotic, in schizophrenia with positive symptomology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology (Berl) 1995; 119: 231-8.
69. Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N. Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin, a new selective 5-HT2 receptor blocking agent. Curr Ther Res 1986; 40: 492-9.
70. Borison RL, Diamond BI, Pathiraja A, Meibach RC. Clinical overview of risperidone. In: Meltzer HY, ed. Novel Antipsychotic Drugs. New York: Raven Press, 1992: 233-9.
71. Cavallaro R, Colombo C, Smeraldi E. A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Hum Psychopharmacol Clin Exp 1995; 10: 231-4.
72. Lewander T. Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Acta Psychiatr Scand 1994; 89 (Suppl 380): 64-7.
73. Ögren SO. Potential mechanisms underlying the atypical antipsychotic profile of remoxipride. In: Palomo T, Archer T, Beninger R, eds. Strategies for Studying Brain Disorders, Vol. 2. London: Farrand Press, 1994: 85-94.
74. Wang S, Sun C, Walczak C, et al. Evidence for a susceptibility locus for schizophrenia on chromosome 6pter-p22. Nat Genet 1995; 10: 41-6.
75. Straub RE, MacLean CJ, O'Niell FA, et al. A potential vulnerability locus for schizophrenia on chromosome 6p24-2: evidence for genetic heterogeneity. Nat Genet 1995; 11: 287-93.
76. Schwab SG, Albus M, Hallmayer J, et al. Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. Nat Genet 1995; 11: 325-7.
77. Moises HW, Yang L, Kristbjarnarson H, et al. An international two-stage genome-wide search for schizophrenia susceptibility genes. Nat Genet 1995; 11: 321-4.